Tetranabinex (BioDeep_00000838356)
代谢物信息卡片
Tetranabinex
化学式: C42H60O4 (628.449136)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O
InChI: 17-,18+/m10/s1
描述信息
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
D002491 - Central Nervous System Agents > D000700 - Analgesics
N - Nervous system > N02 - Analgesics
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Michael R Haupts, Ute Essner, Mathias Mäurer. Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures.
Neurodegenerative disease management.
2024 Feb; 14(1):11-20. doi:
10.2217/nmt-2023-0040. [PMID: 38318862] - Armando Creta, Luana Gilio, Diego Centonze, Roberta Fantozzi. Usability of an application device for nabiximols oromucosal spray in patients with upper limb impaired multiple sclerosis.
Neurodegenerative disease management.
2022 08; 12(4):195-201. doi:
10.2217/nmt-2022-0014. [PMID: 35707977] - Francisco Javier Carod-Artal, Peyman Adjamian, Carlos Vila Silván, Makarand Bagul, Claudio Gasperini. A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis.
Expert review of neurotherapeutics.
2022 06; 22(6):499-511. doi:
10.1080/14737175.2022.2075263. [PMID: 35582858] - Marie D'hooghe, Barbara Willekens, Valerie Delvaux, Miguel D'haeseleer, Daniel Guillaume, Guy Laureys, Guy Nagels, Patrick Vanderdonckt, Vincent Van Pesch, Veronica Popescu. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
BMC neurology.
2021 Jun; 21(1):227. doi:
10.1186/s12883-021-02246-0. [PMID: 34157999] - Florian Lasch, Lorenzo Guizzaro, Lukas Aguirre Dávila, Kirsten Müller-Vahl, Armin Koch. Potential impact of COVID-19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA-TICS study.
Pharmaceutical statistics.
2021 05; 20(3):675-691. doi:
10.1002/pst.2100. [PMID: 33594741] - Friedemann Paul, Carlos Vila Silván. Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity.
Neurodegenerative disease management.
2021 04; 11(2):143-153. doi:
10.2217/nmt-2020-0060. [PMID: 33641348] - Antonella Conte, Carlos Vila Silván. Review of Available Data for the Efficacy and Effectiveness of Nabiximols Oromucosal Spray (Sativex®) in Multiple Sclerosis Patients with Moderate to Severe Spasticity.
Neuro-degenerative diseases.
2021; 21(3-4):55-62. doi:
10.1159/000520560. [PMID: 34731865] - Ivan Urits, Kyle Gress, Karina Charipova, Kelly Habib, David Lee, Christopher Lee, Jai Won Jung, Hisham Kassem, Elyse Cornett, Antonella Paladini, Giustino Varrassi, Alan D Kaye, Omar Viswanath. Use of cannabidiol (CBD) for the treatment of chronic pain.
Best practice & research. Clinical anaesthesiology.
2020 Sep; 34(3):463-477. doi:
10.1016/j.bpa.2020.06.004. [PMID: 33004159] - María Fernández-Trapero, Carmen Pérez-Díaz, Francisco Espejo-Porras, Eva de Lago, Javier Fernández-Ruiz. Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders.
Biomolecules.
2020 02; 10(2):. doi:
10.3390/biom10020279. [PMID: 32054131] - Luigia Cristino, Tiziana Bisogno, Vincenzo Di Marzo. Cannabinoids and the expanded endocannabinoid system in neurological disorders.
Nature reviews. Neurology.
2020 01; 16(1):9-29. doi:
10.1038/s41582-019-0284-z. [PMID: 31831863] - Nicola Specchio, Nicola Pietrafusa, Helen J Cross. Source of cannabinoids: what is available, what is used, and where does it come from?.
Epileptic disorders : international epilepsy journal with videotape.
2020 Jan; 22(S1):1-9. doi:
10.1684/epd.2019.1121. [PMID: 31941643] - Jacob Atsmon, Daphna Heffetz, Lisa Deutsch, Frederic Deutsch, Hagit Sacks. Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology.
Clinical pharmacology in drug development.
2018 09; 7(7):751-758. doi:
10.1002/cpdd.408. [PMID: 29125702] - Anjali K Bhardwaj, David J Allsop, Jan Copeland, Iain S McGregor, Adrian Dunlop, Marian Shanahan, Raimondo Bruno, Nghi Phung, Mark Montebello, Craig Sadler, Jessica Gugusheff, Melissa Jackson, Jennifer Luksza, Nicholas Lintzeris. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.
BMC psychiatry.
2018 05; 18(1):140. doi:
10.1186/s12888-018-1682-2. [PMID: 29776349] - Jacob Atsmon, Irina Cherniakov, Dvora Izgelov, Amnon Hoffman, Abraham J Domb, Lisa Deutsch, Frederic Deutsch, Daphna Heffetz, Hagit Sacks. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
Journal of pharmaceutical sciences.
2018 05; 107(5):1423-1429. doi:
10.1016/j.xphs.2017.12.020. [PMID: 29287930] - N Krcevski-Skvarc, C Wells, W Häuser. Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation.
European journal of pain (London, England).
2018 03; 22(3):440-454. doi:
10.1002/ejp.1147. [PMID: 29134767] - Suzanne Nielsen, Rada Germanos, Megan Weier, John Pollard, Louisa Degenhardt, Wayne Hall, Nicholas Buckley, Michael Farrell. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews.
Current neurology and neuroscience reports.
2018 02; 18(2):8. doi:
10.1007/s11910-018-0814-x. [PMID: 29442178] - Jørgen G Bramness, Geert Dom, Antoni Gual, Karl Mann, Friedrich Martin Wurst. A Survey on the Medical Use of Cannabis in Europe: A Position Paper.
European addiction research.
2018; 24(4):201-205. doi:
10.1159/000492757. [PMID: 30134238] - Tomáš Hložek, Libor Uttl, Lukáš Kadeřábek, Marie Balíková, Eva Lhotková, Rachel R Horsley, Pavlína Nováková, Klára Šíchová, Kristýna Štefková, Filip Tylš, Martin Kuchař, Tomáš Páleníček. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.
2017 12; 27(12):1223-1237. doi:
10.1016/j.euroneuro.2017.10.037. [PMID: 29129557] - Margherita Russo, Vincenzo Dattola, Anna Lisa Logiudice, Rosella Ciurleo, Edoardo Sessa, Rosaria De Luca, Placido Bramanti, Alessia Bramanti, Antonino Naro, Rocco Salvatore Calabrò. The role of Sativex in robotic rehabilitation in individuals with multiple sclerosis: Rationale, study design, and methodology.
Medicine.
2017 Nov; 96(46):e8826. doi:
10.1097/md.0000000000008826. [PMID: 29145345] - R Androvicova, J Horacek, J Tintera, J Hlinka, J Rydlo, D Jezova, M Balikova, T Hlozek, P Miksatkova, M Kuchar, M Roman, P Tomicek, F Tyls, M Viktorinova, T Palenicek. Individual prolactin reactivity modulates response of nucleus accumbens to erotic stimuli during acute cannabis intoxication: an fMRI pilot study.
Psychopharmacology.
2017 Jul; 234(13):1933-1943. doi:
10.1007/s00213-017-4601-1. [PMID: 28401285] - You-Ping Zhu. [European Union regulatory and quality requirements for botanical drugs and their implications for Chinese herbal medicinal products development].
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.
2017 Jun; 42(11):2187-2192. doi:
10.19540/j.cnki.cjcmm.20170316.001. [PMID: 28822167] - Evan C Rosenberg, Pabitra H Patra, Benjamin J Whalley. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
Epilepsy & behavior : E&B.
2017 05; 70(Pt B):319-327. doi:
10.1016/j.yebeh.2016.11.006. [PMID: 28190698] - Valérie Wolff, Emilie Jouanjus. Strokes are possible complications of cannabinoids use.
Epilepsy & behavior : E&B.
2017 05; 70(Pt B):355-363. doi:
10.1016/j.yebeh.2017.01.031. [PMID: 28237318] - Jane B Allendorfer, Jerzy P Szaflarski. Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy.
Epilepsy & behavior : E&B.
2017 05; 70(Pt B):349-354. doi:
10.1016/j.yebeh.2016.11.020. [PMID: 28109780] - Mauro Maccarrone, Rafael Maldonado, Miguel Casas, Thomas Henze, Diego Centonze. Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?.
Expert review of clinical pharmacology.
2017 Apr; 10(4):443-455. doi:
10.1080/17512433.2017.1292849. [PMID: 28276775] - A Carotenuto, R Iodice, M Petracca, M Inglese, I Cerillo, S Cocozza, C Saiote, A Brunetti, E Tedeschi, F Manganelli, G Orefice. Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex®.
Acta neurologica Scandinavica.
2017 Apr; 135(4):442-448. doi:
10.1111/ane.12660. [PMID: 27500463] - Gillian M Keating. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity.
Drugs.
2017 Apr; 77(5):563-574. doi:
10.1007/s40265-017-0720-6. [PMID: 28293911] - Sara Valdeolivas, Onintza Sagredo, Mercedes Delgado, Miguel A Pozo, Javier Fernández-Ruiz. Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.
International journal of molecular sciences.
2017 Mar; 18(4):. doi:
10.3390/ijms18040684. [PMID: 28333097] - Silvia Messina, Claudio Solaro, Isabella Righini, Roberto Bergamaschi, Simona Bonavita, Roberto Bruno Bossio, Vincenzo Brescia Morra, Gianfranco Costantino, Paola Cavalla, Diego Centonze, Giancarlo Comi, Salvatore Cottone, Maura Chiara Danni, Ada Francia, Alberto Gajofatto, Claudio Gasperini, Mauro Zaffaroni, Loredana Petrucci, Elisabetta Signoriello, Giorgia Teresa Maniscalco, Gabriella Spinicci, Manuela Matta, Massimiliano Mirabella, Graziella Pedà, Letizia Castelli, Marco Rovaris, Edoardo Sessa, Daniele Spitaleri, Damiano Paolicelli, Alfredo Granata, Mario Zappia, Francesco Patti. Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).
PloS one.
2017; 12(8):e0180651. doi:
10.1371/journal.pone.0180651. [PMID: 28763462] - Alessandra Morano, Pierangelo Cifelli, Paolo Nencini, Letizia Antonilli, Jinane Fattouch, Gabriele Ruffolo, Cristina Roseti, Eleonora Aronica, Cristina Limatola, Carlo Di Bonaventura, Eleonora Palma, Anna Teresa Giallonardo. Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin.
Epilepsia open.
2016 12; 1(3-4):145-151. doi:
10.1002/epi4.12015. [PMID: 29588939] - Peter Flachenecker. Evolution of multiple sclerosis spasticity-associated symptoms: latest data.
Neurodegenerative disease management.
2016 Dec; 6(6s):9-12. doi:
10.2217/nmt-2016-0047. [PMID: 27874495] - Giovanna Squintani, Francesco Donato, Mara Turri, Luciano Deotto, Francesco Teatini, Giuseppe Moretto, Roberto Erro. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
Journal of the neurological sciences.
2016 Nov; 370(?):263-268. doi:
10.1016/j.jns.2016.09.054. [PMID: 27772772] - F Patti, S Messina, C Solaro, M P Amato, R Bergamaschi, S Bonavita, R Bruno Bossio, V Brescia Morra, G F Costantino, P Cavalla, D Centonze, G Comi, S Cottone, M Danni, A Francia, A Gajofatto, C Gasperini, A Ghezzi, A Iudice, G Lus, G T Maniscalco, M G Marrosu, M Matta, M Mirabella, E Montanari, C Pozzilli, M Rovaris, E Sessa, D Spitaleri, M Trojano, P Valentino, M Zappia. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.
Journal of neurology, neurosurgery, and psychiatry.
2016 Sep; 87(9):944-51. doi:
10.1136/jnnp-2015-312591. [PMID: 27160523] - Francesca Indorato, Aldo Liberto, Caterina Ledda, Guido Romano, Nunziata Barbera. The therapeutic use of cannabinoids: Forensic aspects.
Forensic science international.
2016 Aug; 265(?):200-3. doi:
10.1016/j.forsciint.2016.03.031. [PMID: 27038587] - Hannah M Harris, Kenneth J Sufka, Waseem Gul, Mahmoud A ElSohly. Effects of Delta-9-Tetrahydrocannabinol and Cannabidiol on Cisplatin-Induced Neuropathy in Mice.
Planta medica.
2016 Aug; 82(13):1169-72. doi:
10.1055/s-0042-106303. [PMID: 27214593] - ". Cannabis and cannabinoids.
The Medical letter on drugs and therapeutics.
2016 Aug; 58(1500):97-8. doi:
". [PMID: 27466748] - Jose Luis López-Sendón Moreno, Juan García Caldentey, Patricia Trigo Cubillo, Carolina Ruiz Romero, Guillermo García Ribas, M A Alonso Alonso Arias, María Jesús García de Yébenes, Rosa María Tolón, Ismael Galve-Roperh, Onintza Sagredo, Sara Valdeolivas, Eva Resel, Silvia Ortega-Gutierrez, María Laura García-Bermejo, Javier Fernández Ruiz, Manuel Guzmán, Justo García de Yébenes Prous. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.
Journal of neurology.
2016 Jul; 263(7):1390-400. doi:
10.1007/s00415-016-8145-9. [PMID: 27159993] - Jose M Trigo, Alexandra Soliman, Gregory Staios, Lena Quilty, Benedikt Fischer, Tony P George, Jürgen Rehm, Peter Selby, Allan J Barnes, Marilyn A Huestis, Bernard Le Foll. Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series.
Journal of addiction medicine.
2016 Jul; 10(4):274-9. doi:
10.1097/adm.0000000000000229. [PMID: 27261670] - M Russo, R De Luca, M Torrisi, C Rifici, E Sessa, P Bramanti, A Naro, R S Calabrò. Should we care about sativex-induced neurobehavioral effects? A 6-month follow-up study.
European review for medical and pharmacological sciences.
2016 07; 20(14):3127-33. doi:
". [PMID: 27460745] - Margherita Russo, Antonino Naro, Antonino Leo, Edoardo Sessa, Giangaetano D'Aleo, Placido Bramanti, Rocco Salvatore Calabrò. Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.
Pain medicine (Malden, Mass.).
2016 06; 17(6):1145-54. doi:
10.1093/pm/pnv080. [PMID: 26764336] - Anna Molnar, Shanlin Fu. Techniques and technologies for the bioanalysis of Sativex®, metabolites and related compounds.
Bioanalysis.
2016 Apr; 8(8):829-45. doi:
10.4155/bio-2015-0021. [PMID: 27005853] - Jose M Trigo, Dina Lagzdins, Jürgen Rehm, Peter Selby, Islam Gamaleddin, Benedikt Fischer, Allan J Barnes, Marilyn A Huestis, Bernard Le Foll. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.
Drug and alcohol dependence.
2016 Apr; 161(?):298-306. doi:
10.1016/j.drugalcdep.2016.02.020. [PMID: 26925704] - J Ablin, P A Ste-Marie, M Schäfer, W Häuser, M-A Fitzcharles. Medical use of cannabis products: Lessons to be learned from Israel and Canada.
Schmerz (Berlin, Germany).
2016 Feb; 30(1):3-13. doi:
10.1007/s00482-015-0083-4. [PMID: 26767992] - Michael Haupts, Carlos Vila, Anna Jonas, Kerstin Witte, Lourdes Álvarez-Ossorio. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
European neurology.
2016; 75(5-6):236-43. doi:
10.1159/000445943. [PMID: 27160412] - Óscar Fernández. THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.
European neurology.
2016; 75 Suppl 1(?):1-3. doi:
10.1159/000444234. [PMID: 26901342] - Maria Trojano. THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
European neurology.
2016; 75 Suppl 1(?):4-8. doi:
10.1159/000444235. [PMID: 26901343] - Francesco Patti. Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.
European neurology.
2016; 75 Suppl 1(?):9-12. doi:
10.1159/000444236. [PMID: 26901344] - Patrick Vermersch, Maria Trojano. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
European neurology.
2016; 76(5-6):216-226. doi:
10.1159/000449413. [PMID: 27732980] - Letizia Leocani, Arturo Nuara, Elise Houdayer, Irene Schiavetti, Ubaldo Del Carro, Stefano Amadio, Laura Straffi, Paolo Rossi, Vittorio Martinelli, Carlos Vila, Maria Pia Sormani, Giancarlo Comi. Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
Journal of neurology.
2015 Nov; 262(11):2520-7. doi:
10.1007/s00415-015-7878-1. [PMID: 26289497] - Miguel Moreno-Martet, Ana Feliú, Francisco Espejo-Porras, Miriam Mecha, Francisco J Carrillo-Salinas, Javier Fernández-Ruiz, Carmen Guaza, Eva de Lago. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.
Multiple sclerosis and related disorders.
2015 Nov; 4(6):505-11. doi:
10.1016/j.msard.2015.08.001. [PMID: 26590655] - Clementino Ibeas Bih, Tong Chen, Alistair V W Nunn, Michaël Bazelot, Mark Dallas, Benjamin J Whalley. Molecular Targets of Cannabidiol in Neurological Disorders.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
2015 Oct; 12(4):699-730. doi:
10.1007/s13311-015-0377-3. [PMID: 26264914] - Stephanie Pain. A potted history.
Nature.
2015 Sep; 525(7570):S10-1. doi:
10.1038/525s10a. [PMID: 26398731] - Brian Owens. Drug development: The treasure chest.
Nature.
2015 Sep; 525(7570):S6-8. doi:
10.1038/525s6a. [PMID: 26398738] - A Feliú, M Moreno-Martet, M Mecha, F J Carrillo-Salinas, E de Lago, J Fernández-Ruiz, C Guaza. A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.
British journal of pharmacology.
2015 Jul; 172(14):3579-95. doi:
10.1111/bph.13159. [PMID: 25857324] - Jane L Armstrong, David S Hill, Christopher S McKee, Sonia Hernandez-Tiedra, Mar Lorente, Israel Lopez-Valero, Maria Eleni Anagnostou, Fiyinfoluwa Babatunde, Marco Corazzari, Christopher P F Redfern, Guillermo Velasco, Penny E Lovat. Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death.
The Journal of investigative dermatology.
2015 Jun; 135(6):1629-1637. doi:
10.1038/jid.2015.45. [PMID: 25674907] - John Slof, Leonardo Ruiz, Carlos Vila. Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.
Expert review of pharmacoeconomics & outcomes research.
2015 Jun; 15(3):379-91. doi:
10.1586/14737167.2015.1025759. [PMID: 25771713] - C Lebrun, P Vermersch. [A breakthrough for the treatment of spasticity in multiple sclerosis].
Revue neurologique.
2015 Apr; 171(4):327-8. doi:
10.1016/j.neurol.2015.03.002. [PMID: 25835097] - Icíar Cimas-Hernando, Antonio Pato-Pato, José R Lorenzo-González, Iria Rodríguez-Constenla. [Assessment of the effectiveness and safety of Sativex® in compassionate use].
Revista de neurologia.
2015 Mar; 60(5):202-6. doi:
". [PMID: 25710689] - Patrick Vermersch. Advances in the management of MS symptoms: recently proposed clinical management algorithms.
Neurodegenerative disease management.
2015; 5(6 Suppl):23-6. doi:
10.2217/nmt.15.57. [PMID: 26611268] - M Freidel, K Tiel-Wilck, H Schreiber, A Prechtl, U Essner, M Lang. Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.
Acta neurologica Scandinavica.
2015 Jan; 131(1):9-16. doi:
10.1111/ane.12287. [PMID: 25208898] - Margherita Russo, Rocco Salvatore Calabrò, Antonino Naro, Edoardo Sessa, Carmela Rifici, Giangaetano D'Aleo, Antonino Leo, Rosaria De Luca, Angelo Quartarone, Placido Bramanti. Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation.
Neural plasticity.
2015; 2015(?):656582. doi:
10.1155/2015/656582. [PMID: 25699191] - Sven G Meuth, Carlos Vila, Kerry L Dechant. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.
Expert review of neurotherapeutics.
2015; 15(8):909-18. doi:
10.1586/14737175.2015.1067607. [PMID: 26166264] - Maria Trojano, Carlos Vila. Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
European neurology.
2015; 74(3-4):178-85. doi:
10.1159/000441619. [PMID: 26571097] - Maria Trojano. Advances in the management of MS symptoms: real-life evidence.
Neurodegenerative disease management.
2015; 5(6 Suppl):19-21. doi:
10.2217/nmt.15.66. [PMID: 26611267] - Irene Moreno Torres, Antonio J Sanchez, Antonio Garcia-Merino. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
Expert review of neurotherapeutics.
2014 Nov; 14(11):1243-50. doi:
10.1586/14737175.2014.971758. [PMID: 25331416] - Miguel Moreno-Martet, Francisco Espejo-Porras, Javier Fernández-Ruiz, Eva de Lago. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(®) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis.
CNS neuroscience & therapeutics.
2014 Sep; 20(9):809-15. doi:
10.1111/cns.12262. [PMID: 24703394] - Rafael Arroyo, Carlos Vila, Kerry L Dechant. Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity.
Journal of comparative effectiveness research.
2014 Jul; 3(4):435-44. doi:
10.2217/cer.14.30. [PMID: 25275238] - Anna Molnar, Shanlin Fu, John Lewis, David J Allsop, Jan Copeland. The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
Forensic science international.
2014 May; 238(?):113-9. doi:
10.1016/j.forsciint.2014.03.004. [PMID: 24699310] - Yahiya Y Syed, Kate McKeage, Lesley J Scott. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
Drugs.
2014 Apr; 74(5):563-78. doi:
10.1007/s40265-014-0197-5. [PMID: 24671907] - Allan J Barnes, Karl B Scheidweiler, Marilyn A Huestis. Quantification of 11-nor-9-carboxy-δ9-tetrahydrocannabinol in human oral fluid by gas chromatography-tandem mass spectrometry.
Therapeutic drug monitoring.
2014 Apr; 36(2):225-33. doi:
10.1097/01.ftd.0000443071.30662.01. [PMID: 24622724] - Amine Benyamina, Michel Reynaud. [Therapeutic use of cannabis derivatives].
La Revue du praticien.
2014 Feb; 64(2):165-8. doi:
". [PMID: 24701869] - Carlo Pozzilli. Overview of MS spasticity.
European neurology.
2014; 71 Suppl 1(?):1-3. doi:
10.1159/000357739. [PMID: 24457845] - Tiina Rekand. THC:CBD spray and MS spasticity symptoms: data from latest studies.
European neurology.
2014; 71 Suppl 1(?):4-9. doi:
10.1159/000357742. [PMID: 24457846] - Jürgen Koehler. Who benefits most from THC:CBD spray? Learning from clinical experience.
European neurology.
2014; 71 Suppl 1(?):10-5. doi:
10.1159/000357743. [PMID: 24457847] - Peter Flachenecker, Thomas Henze, Uwe K Zettl. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
European neurology.
2014; 71(5-6):271-9. doi:
10.1159/000357427. [PMID: 24525548] - Barbara Erbe. [Cannabis - medicinal use].
Deutsche medizinische Wochenschrift (1946).
2014 Jan; 139(3):74-5. doi:
10.1055/s-0033-1353961. [PMID: 24555193] - Diego Centonze. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity nervous pathways.
European neurology.
2014; 72 Suppl 1(?):6-8. doi:
10.1159/000367615. [PMID: 25278116] - Oscar Fernández. Advances in the management of multiple sclerosis spasticity: recent clinical trials.
European neurology.
2014; 72 Suppl 1(?):9-11. doi:
10.1159/000367616. [PMID: 25278117] - Oscar Fernández. Advances in the management of MS spasticity: recent observational studies.
European neurology.
2014; 72 Suppl 1(?):12-4. doi:
10.1159/000367618. [PMID: 25278118] - Maria Trojano, Elisabeth G Celius, Cecile Donzé, Guillermo Izquierdo, Francesco Patti, Dieter Pöhlau. Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.
European neurology.
2014; 72 Suppl 1(?):15-9. doi:
10.1159/000367619. [PMID: 25278119] - Jürgen Koehler, Maria P Amato, Celia Oreja-Guevara, Jan Lycke. Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe.
Expert review of neurotherapeutics.
2013 Dec; 13(12 Suppl):61-6. doi:
10.1586/14737175.2013.865881. [PMID: 24289846] - Radu Tanasescu, Cris S Constantinescu. Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain.
Expert opinion on drug metabolism & toxicology.
2013 Sep; 9(9):1219-28. doi:
10.1517/17425255.2013.795542. [PMID: 23621668] - Dayong Lee, Erin L Karschner, Garry Milman, Allan J Barnes, Robert S Goodwin, Marilyn A Huestis. Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?.
Drug and alcohol dependence.
2013 Jun; 130(1-3):68-76. doi:
10.1016/j.drugalcdep.2012.10.011. [PMID: 23146820] - C G Stott, L White, S Wright, D Wilbraham, G W Guy. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.
European journal of clinical pharmacology.
2013 May; 69(5):1135-47. doi:
10.1007/s00228-012-1441-0. [PMID: 23179176] - William G Notcutt. A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine.
Primary health care research & development.
2013 Apr; 14(2):192-9. doi:
10.1017/s1463423612000333. [PMID: 22784399] - M I Vicente-Valor, P Garcia-Llopis, L Mejia Andujar, G Antonino de la Camara, N García del Busto, M J Lopez Tinoco, B Quintana Vergara, C Peiro Vilaplana, J A Dominguez Moran, A Sánchez Alcaraz. Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report.
Journal of clinical pharmacy and therapeutics.
2013 Feb; 38(1):71-3. doi:
10.1111/j.1365-2710.2012.01365.x. [PMID: 22726074] - Maria Trojano. Multiple sclerosis spasticity symptoms management. Endocannabinoid system modulator data beyond clinical trials. Foreword.
Expert review of neurotherapeutics.
2013 Feb; 13(3 Suppl 1):1. doi:
10.1586/ern.13.2. [PMID: 23369052] - Antonio García-Merino. Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain.
Expert review of neurotherapeutics.
2013 Feb; 13(3 Suppl 1):9-13. doi:
10.1586/ern.13.4. [PMID: 23369054] - Peter Flachenecker. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
Expert review of neurotherapeutics.
2013 Feb; 13(3 Suppl 1):15-9. doi:
10.1586/ern.13.1. [PMID: 23369055] - Michael G Serpell, William Notcutt, Christine Collin. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.
Journal of neurology.
2013 Jan; 260(1):285-95. doi:
10.1007/s00415-012-6634-z. [PMID: 22878432] - Maria J Casarejos, Juan Perucho, Ana Gomez, Maria P Muñoz, Marian Fernandez-Estevez, Onintza Sagredo, Javier Fernandez Ruiz, Manuel Guzman, Justo Garcia de Yebenes, Maria A Mena. Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy.
Journal of Alzheimer's disease : JAD.
2013; 35(3):525-39. doi:
10.3233/jad-130050. [PMID: 23478312] - Lars Gramstad, Anne S Onsgård Sagabråten. [Cannabis medicines in Norway--the basis for approval].
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.
2012 Dec; 132(23-24):2598-9. doi:
10.4045/tidsskr.12.1250. [PMID: 23338087] - ". What place for ▾ cannabis extract in MS?.
Drug and therapeutics bulletin.
2012 Dec; 50(12):141-4. doi:
10.1136/dtb.2012.11.0150. [PMID: 23241565] - Lanting Lu, Hilary Pearce, Chris Roome, James Shearer, Iain A Lang, Ken Stein. Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.
PharmacoEconomics.
2012 Dec; 30(12):1157-71. doi:
10.2165/11598470-000000000-00000. [PMID: 23072659] - Giulio Podda, Cris S Constantinescu. Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
Expert opinion on biological therapy.
2012 Nov; 12(11):1517-31. doi:
10.1517/14712598.2012.721765. [PMID: 22954177] - Stephen Wright, Paul Duncombe, Douglas G Altman. Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach.
Trials.
2012 Oct; 13(?):189. doi:
10.1186/1745-6215-13-189. [PMID: 23046749] - Celia Oreja-Guevara. [Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].
Revista de neurologia.
2012 Oct; 55(7):421-30. doi:
". [PMID: 23011861] - John Slof, Adrien Gras. Sativex® in multiple sclerosis spasticity: a cost-effectiveness model.
Expert review of pharmacoeconomics & outcomes research.
2012 Aug; 12(4):439-41. doi:
10.1586/erp.12.40. [PMID: 22681512] - Sara Valdeolivas, Valentina Satta, Roger G Pertwee, Javier Fernández-Ruiz, Onintza Sagredo. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.
ACS chemical neuroscience.
2012 May; 3(5):400-6. doi:
10.1021/cn200114w. [PMID: 22860209]